Redx Pharma plc Exercise of Options, PDMR Dealing and TVR (8023T)
July 26 2022 - 8:47AM
UK Regulatory
TIDMREDX
RNS Number : 8023T
Redx Pharma plc
26 July 2022
REDX PHARMA PLC
("Redx" or "the Company")
Exercise of Options, PDMR Dealing and Total Voting Rights
Alderley Park, UK, 26 July 2022 Redx (AIM:REDX), the
clinical-stage biotechnology company focused on discovering and
developing novel, small molecule, highly targeted therapeutics for
the treatment of cancer and fibrotic disease, announces the
exercise of share options by current and former employees of the
Company over a total of 1,058,297 new ordinary shares of 1 pence
each in the capital of the Company ("Ordinary Shares") at exercise
prices ranging from 15.5 to 56 pence per share.
In addition, options over 500,000 new ordinary shares of 1 pence
each in the capital of the Company were exercised by Richard Armer
(Chief Scientific Officer) who is classed as a person discharging
managerial responsibility ("PDMR") under EU Regulation 596/2014 as
it forms part of domestic law in the United Kingdom by virtue of
the European Union (Withdrawal) Act 2018, as set out further
below.
Name Position Number of Exercise price Total options
share options held following
exercised exercise
Chief Scientific
Richard Armer Officer 500,000 15.5 pence 6,084,378
------------------ --------------- --------------- ----------------
Application has been made to the London Stock Exchange for the
1,558,297 new Ordinary Shares to be admitted to trading on AIM and
admission is expected to occur at or around 8.00 am on Wednesday
27(th) July 2022. The new Ordinary Shares will rank pari passu with
the existing Ordinary Shares in issue.
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency
Rules, following the above issue of equity, the issued share
capital of the Company will comprise 334,911,458 Ordinary Shares.
The above figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest in, or a change in their interest in, the
Company, under the Disclosure Guidance and Transparency Rules.
For further information, please
contact:
Redx Pharma Plc T: +44 (0)1625 469
UK Headquarters 918
Caitlin Pearson, Head of Communications
ir@redxpharma.com
Lisa Anson, Chief Executive Officer
US Office
Peter Collum, Chief Financial Officer
SPARK Advisory Partners (Nominated Adviser) T: +44 (0)203 368 3550
Matt Davis/ Adam Dawes
WG Partners LLP (Joint Broker) T: +44 (0)203 705 9330
Claes Spång/ Satheesh Nadarajah/ David
Wilson
Panmure Gordon (UK) Limited (Joint Broker) T: +44 (0)207 886 2500
Rupert Dearden/ Freddy Crossley/ Emma Earl
FTI Consulting T: +44 (0)203 727 1000
Simon Conway/ Ciara Martin
About Redx Pharma Plc
Redx Pharma (AIM: REDX) is a clinical-stage biotechnology
company focused on the discovery and development of novel, small
molecule, highly targeted therapeutics for the treatment of cancer
and fibrotic diseases, aiming initially to progress them to
clinical proof of concept before evaluating options for further
development and potential value creation. Redx's lead oncology
product candidate, the Porcupine inhibitor RXC004, commenced a
Phase 2 programme in November 2021. The Company's lead fibrosis
product candidate, the selective ROCK2 inhibitor RXC007, is in
development for idiopathic pulmonary fibrosis and commenced a Phase
1 clinical trial in June 2021. Encouraging safety and
pharmacokinetic data has been reported, and a Phase 2 clinical
programme is confirmed to start in 2022. Redx's third drug
candidate, RXC008, a GI-targeted ROCK inhibitor for the treatment
of fibrostenotic Crohn's disease, is currently in pre-IND stage,
with Phase 1 clinical studies expected to commence in 2023.
The Company has a strong track record of discovering new drug
candidates through its core strengths in medicinal chemistry and
translational science, enabling the Company to discover and develop
differentiated therapeutics against biologically or clinically
validated targets. The Company's accomplishments are evidenced not
only by its two wholly-owned clinical-stage product candidates and
rapidly expanding pipeline, but also by its strategic transactions,
including the sale of pirtobrutinib (RXC005, LOXO-305), a BTK
inhibitor now in Phase 3 clinical development by Eli Lilly
following its acquisition of Loxo Oncology and AZD5055/RXC006, a
Porcupine inhibitor targeting fibrotic diseases including
idiopathic pulmonary fibrosis (IPF), which AstraZeneca is
progressing in a Phase 1 clinical study. In addition, Redx has
forged collaborations with Jazz Pharmaceuticals, which includes
JZP815, a preclinical pan-RAF inhibitor, which has received IND
approval and a further oncology programme which is in early stage
research.
To subscribe to Email Alerts from Redx, please visit:
www.redxpharma.com/investor-centre/email-alerts/
1. Details of the person discharging managerial responsibilities/person
closely associated
a) Name Richard Armer
--------------------------------- ------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------
a) Position/status Chief Scientific Officer
--------------------------------- ------------------------------------
b) Initial notification/Amendment Initial Notification
--------------------------------- ------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name Redx Pharma Plc
--------------------------------- ------------------------------------
b) LEI 213800HMS4EBXO589Y37
--------------------------------- ------------------------------------
4. Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been
conducted
-----------------------------------------------------------------------
a) Description of the financial Ordinary Shares of 1p each
instrument
--------------------------------- ------------------------------------
b) Identification code ISIN: GB00BSNB6S51
--------------------------------- ------------------------------------
c) Nature of the transactions Exercise of options under the Redx
Share Option Scheme
--------------------------------- ------------------------------------
d) Price(s) and volume(s) Exercise Price: 15.5p per share
Volume: 500,000
--------------------------------- ------------------------------------
e) Aggregated information As for d) above
- Aggregated volume
- Price
--------------------------------- ------------------------------------
f) Date of the transactions 26 July 2022
--------------------------------- ------------------------------------
f) Place of the transactions Off-market
--------------------------------- ------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCBDGDRLSDDGDL
(END) Dow Jones Newswires
July 26, 2022 08:47 ET (12:47 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2023 to Apr 2024
